论文部分内容阅读
目的:分析整合素αvβ6在中国与孟加拉国乳腺癌标本中的表达情况。方法:免疫组化方法检测78例中国患者及42例孟加拉患者的乳腺癌标本及癌旁组织中αvβ6的表达情况,并统计分析其临床意义。结果:整合素αvβ6的表达情况与病理组织分级(中国患者组P=0.032,孟加拉患者组P=0.013)、腋淋巴结受累情况(中国患者组P=0.010,孟加拉患者组P=0.001)密切相关。利用Kaplan-Meier检验进行生存分析发现,与整合素αvβ6表达阴性患者相比,整合素αvβ6表达阳性患者中位生存期显著降低(中国患者组P=0.021,孟加拉患者组P=0.002,log-rank检验)。结论:在中国与孟加拉国,整合素αvβ6均为乳腺癌浸润与转移的标记物,将来有望成为乳腺癌治疗的靶点。
OBJECTIVE: To analyze the expression of integrin αvβ6 in breast cancer specimens from China and Bangladesh. Methods: Immunohistochemistry was used to detect the expression of αvβ6 in breast cancer samples and adjacent normal tissues in 78 Chinese patients and 42 Bangladeshi patients. The clinical significance was analyzed statistically. Results: The expression of integrin αvβ6 was closely related to the pathological grade (P = 0.032 in Chinese patients and P = 0.013 in Bangladeshi patients), and the involvement of axillary lymph nodes (P = 0.010 in Chinese patients and P = 0.001 in Bangladeshi patients). Survival analysis using the Kaplan-Meier test showed a significantly lower median survival in patients with positive integrin αvβ6 expression compared with those with negative αvβ6 expression (P = 0.021 for Chinese patients, P = 0.002 for logistic regression for Bangladesh patients test). CONCLUSIONS: In China and Bangladesh, integrin αvβ6 is a marker of breast cancer invasion and metastasis and may be the target of breast cancer therapy in the future.